Tarsus Pharmaceuticals (TARS) Cash from Financing Activities (2019 - 2026)

Tarsus Pharmaceuticals' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 99.12% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $8.0 million, a 95.6% decrease from a year earlier, with the FY2025 full-year figure at $143.4 million, down 7.29% from the prior year.
• Cash from Financing Activities slipped to $1.2 million in Q1 2026 per TARS's latest filing, from $2.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $136.6 million in Q1 2025 and bottomed at -$136000.0 in Q3 2022.
• The 5-year median for Cash from Financing Activities is $2.9 million (2024), against an average of $30.8 million.
• Biggest YoY gain for Cash from Financing Activities was 7473300.0% in 2022; the steepest drop was 281.33% in 2022.
• Year by year, Cash from Financing Activities stood at $264000.0 in 2022, then soared by 7384.85% to $19.8 million in 2023, then sank by 85.19% to $2.9 million in 2024, then retreated by 21.01% to $2.3 million in 2025, then tumbled by 47.92% to $1.2 million in 2026.
• Per Business Quant, the three latest TARS Cash from Financing Activities figures stand at $1.2 million (Q1 2026), $2.3 million (Q4 2025), and $2.6 million (Q3 2025).